v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
OPERATING EXPENSES:    
Research and development $ 118,436 $ 119,039
General and administrative 60,601 59,166
Total operating expenses 179,037 178,205
LOSS FROM OPERATIONS: (179,037) (178,205)
OTHER (EXPENSE) INCOME, NET:    
Fair value change of warrant liabilities (122,561) 0
Benefit from R&D tax credit 3,747 21,097
Interest income 7,182 8,268
Interest expense (4,517) (4,479)
Foreign exchange gains (losses) 3,471 (1,032)
Other income 1,380 823
Total other (expense) income, net (111,298) 24,677
Loss before income taxes (290,335) (153,528)
Income tax benefit (expense) 2,473 (1,594)
Net loss $ (287,862) $ (155,122)
Net loss per share attributable to ordinary shareholders - basic (in dollars per share) $ (3.08) $ (2.30)
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share) $ (3.08) $ (2.30)
Weighted average ordinary shares outstanding - basic (in shares) 93,504,836 67,482,902
Weighted average ordinary shares outstanding - diluted (in shares) 93,504,836 67,482,902
Net loss $ (287,862) $ (155,122)
Other comprehensive loss:    
Foreign exchange translation adjustment 1,405 732
Comprehensive loss $ (286,457) $ (154,390)